Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Migraine: Tricks of the Trade

neuroscienceCME Multimedia Snack

Premiere Date: Monday, July 9, 2012

This activity offers CE credit for:

1. Physicians (CME)
2. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Tuesday, July 9, 2013
Note: Credit Is No Longer Available

Faculty

Charles B. Nemeroff, MD, PhD  Professor and Chair Department of Psychiatry Mulva Clinic for the Neurosciences Director, Institute of Early Life Adversity Research Dell Medical School The University of Texas at Austin Austin, TX

Michael A. Rogawski, MD, PhD  Professor and Chair Department of Neurology University of California, Davis Sacramento, CA

---

Co-provided by

 

Statement of Need

The accurate clinical diagnosis of migraine is based on International Headache Society (HIS) criteria. However, failure to recognize and diagnose migraine according to HIS criteria occurs with alarmingly frequency.(1) In a patient with recurrent disabling headache, migraine is the most likely diagnosis. However, clinicians must be able to differentiate and identify the symptoms and cardinal features of migraine in order to determine the type of migraine.(2) Treatments for acute attacks can be divided into nonspecific anti-pain compounds, such as simple analgesics and more migraine-specific treatment approaches. Severe, frequent, and disabling migraine attacks, as well as those poorly responsive to acute care medication, require preventive treatment, or prophylaxis, which is often underutilized.(3)

This neuroscienceCME Snack will provide insights into both acute therapy and prophylactic management of migraine headache, and provide clinicians with strategies for the treatment of migraine, which can be applied to clinical practice.

---

1. Landy SH, Kwong WJ, Hutchinson S, Roselli A, Burch SP. Migraine: a better way to recognize and treat it. J Fam Pract. 2006;55(12):1038-1047. PMID: 17137539.
2. Cady RK, Cahill K, Lantin CM, Lipton RB, Sacchetti D, Wenzel RG. NHF Migraine Prevention Summit Proceedings: The Importance of Communicating with Patients. Issue 2. National Headache Foundation.Website. http://www.headaches.org/pdf/NHFNewsletter2.pdf. Published December 2006. Accessed September 1, 2011.
3. Vikelis M, Rapoport AM. Role of antiepileptic drugs as preventive agents for migraine. CNS Drugs. 2010;24(1):21-33. PMID: 20030417.

Activity Goal

The goal of this activity is to provide clinicians with an evidence-based evaluation of best-practice clinical strategies for the treatment of migraine.

Learning Objectives

At the end of this CE activity, participants should be able to:

• Apply best practice strategies in clinical practice for the treatment of migraine.

Financial Support

USF Health and CME Outfitters, LLC, gratefully acknowledge an educational grant from Genentech in support of this CE activity.

This educational activity is supported by an independent medical education grant from Shire.

Supported in part by an educational grant from Endo Pharmaceuticals.

Target Audience

Physicians and other health care professionals with an interest in the management of migraine headache.

Credit Information

CME Credit (Physicians):
USF Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

USF Health designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/test (requires free account activation), and participants can print their certificate or statement of credit immediately (80% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp.

Disclosure Declaration

USF Health and CME Outfitters, LLC, adhere to the ACCME Standards, as well as those of the ACPE, APA, and ANCC, regarding commercial support of continuing medical education. It is the policy of USF Health and CME Outfitters, LLC, that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.

Dr. Nemeroff has disclosed that he receives grants/research support from the Agency for Healthcare Research and Quality (AHRQ) and the National Institutes of Health (NIH). He serves as a consultant to Takeda Pharmaceuticals North America, Inc., and Xhale, Inc. He serves on the advisory boards of the American Foundation for Suicide Prevention (AFSP), the Anxiety Disorders Association of America (ADAA), CeNeRx BioPharma, the National Alliance for Research on Schizophrenia and Depression (NARSAD), NovaDel Pharma, Inc., and PharmaNeuroBoost. He serves on the board of directors of the American Foundation for Suicide Prevention and NovaDel Pharma, Inc. He is a stockholder of CeNeRx BioPharma, Corcept Therapeutics, NovaDel Pharma, Inc., PharmaNeuroBoost, Reevax Pharmaceuticals LLC, and Xhale, Inc. His other financial Interests include CeNeRx BioPharma and PharmaNeuroBoost. He holds patents for the following: method and devices for transdermal delivery of lithium (US 6,375,990B1); method of assessing antidepressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2).

Dr. Rogawski has disclosed that he receives grants from Congressionally Directed Medical Research Programs; Epilepsy Research Foundation (Epilepsy Foundation); National Institute of Neurological Disorders and Stroke; and People Against Childhood Epilepsy, Inc. He receives research support from Eisai Inc.; Forest Research Institute, Inc.; and Gilead Sciences, Inc. He serves as a consultant to Eli Lilly and Company; GlaxoSmithKline; Merck & Co., Inc.; Novartis Corporation; and Pfizer Inc.

Disclosures were obtained from the planning committee members and are on file in the USF Health Office of Continuing Professional Development (OCPD) for review. Disclosures were obtained from the USF Health OCPD staff: Nothing to Disclose.

Howard Bliwise, MD (peer/content reviewer) has no disclosures to report.

Christina Ansted, MPH, CCMEP (planning committee) has no disclosures to report.

Joy Leffler, MLA, NASW, CSE (planning committee) has no disclosures to report.

Sharon Tordoff, CCMEP (planning committee) has no disclosures to report.

Discussion of Off-Label Use: Because this course is meant to educate physicians with what is currently in use and what may be available in the future, there may be off-label use discussed in the presentations. Speakers have been requested to inform the audience when off-label use is being discussed.

Equal Opportunity Statement: Events, activities, programs and facilities of the University of South Florida are available to all without regard to race, color, marital status, gender, sexual orientation, religion, national origin, disability, age, Vietnam or disabled veteran status as provided by law and in accordance with the university's respect for personal dignity.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).